Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 05 - 21 tags : Approval save search
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2021-05-21 (Crawled : 23:00) - biospace.com/
GH M | $16.6 1.28% 360K
|
Health Services
|
| O: 0.53%
H: 2.94%
C: 0.73%
fda lung cancer fda approval cancer approval diagnostic
Genmab Announces that Janssen has been Granted U.S. FDA Approval for RYBREVANT™ (amivantamab-vmjw) for Patients with Metastatic Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations
Published: 2021-05-21 (Crawled : 20:00) - globenewswire.com
GMAB | $28.6 0.25% 77K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
| Email alert
Add to watchlist
fda lung cancer fda approval cancer ev growth approval
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2021-05-21 (Crawled : 19:00) - prnewswire.com
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
| Email alert
Add to watchlist
treatment fda lung cancer fda approval cancer approval
Hematology/Oncology (Cancer) Approvals & Safety Notifications
Published: 2021-05-21 (Crawled : 18:33) - fda.gov
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: 0.22%
H: 0.97%
C: -0.65%
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: 0.36%
H: 1.01%
C: -0.28%
ADCT | $4.74 -4.44% 150K
|
Health Technology
|
| O: 2.54%
H: 0.48%
C: -0.29%
ABBV | $165.54 0.78% 2.2M
|
Health Technology
|
| O: 0.35%
H: 0.65%
C: -1.19%
YMAB | $15.23 0.79% 130K
|
Health Technology
|
| O: 0.58%
H: 1.24%
C: -1.66%
VSTM | $10.67 -1.57% 31K
|
Health Technology
|
| O: 0.63%
H: 2.49%
C: -0.62%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
RIGL | $1.095 -1.35% 230K
|
Health Technology
|
| O: 0.82%
H: 1.08%
C: -1.62%
REGN | $900.22 -0.11% 150K
|
Health Technology
|
| O: 0.18%
H: 0.46%
C: -1.44%
KPTI | $1.345 -2.54% 670K
|
Health Technology
|
| O: 0.31%
H: 1.15%
C: -1.46%
INCY | $52.46 -0.49% 330K
|
Health Technology
|
| O: 0.57%
H: 0.6%
C: -1.46%
ILMN | $118.52 0.19% 530K
|
Health Technology
|
| O: 0.33%
H: 2.2%
C: 0.21%
EXEL | $22.965 0.42% 540K
|
Health Technology
|
| O: 0.08%
H: 1.64%
C: 0.45%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: 1.04%
H: 0.0%
C: -2.62%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.95%
H: 1.31%
C: -2.81%
BPMC | $89.93 1.75% 94K
|
Health Technology
|
| O: 1.12%
H: 0.84%
C: -0.08%
BGNE S | $135.29 2.6% 49K
|
Health Technology
|
| O: 0.1%
H: 1.6%
C: 0.88%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 1.19%
H: 1.71%
C: -0.33%
AMGN | $265.48 0.53% 360K
|
Health Technology
|
| O: 0.71%
H: 0.14%
C: -1.06%
ALNY | $146.09 0.53% 59K
|
Health Technology
|
| O: 0.38%
H: 1.01%
C: -0.41%
AGIO | $29.59 1.93% 170K
|
Health Technology
|
| O: 0.86%
H: 1.27%
C: -0.24%
cancer approval
FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer
Published: 2021-05-21 (Crawled : 18:33) - fda.gov
GH M | $16.6 1.28% 360K
|
Health Services
| Email alert
Add to watchlist
fda cancer approval granted grant
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer
Published: 2021-05-21 (Crawled : 17:00) - prnewswire.com
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
|
| O: 0.15%
H: 0.82%
C: -0.22%
fda lung cancer therapy cancer approval fda approval
NVIDIA Announces Four-for-One Stock Split, Pending Stockholder Approval at Annual Meeting Set for June 3
Published: 2021-05-21 (Crawled : 13:15) - globenewswire.com
NVDA | $858.22 2.13% 23M
|
Electronic Technology
|
| O: 3.77%
H: 0.38%
C: -1.13%
approval
TypTap Receives Approval to Write Homeowners Insurance in Massachusetts as Part of Company’s Nationwide Expansion Plan
Published: 2021-05-21 (Crawled : 12:15) - globenewswire.com
HCI P | $110.575 0.61% 42K
|
Finance
|
| O: 0.59%
H: 1.13%
C: -0.57%
expansion approval insurance
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
Published: 2021-05-21 (Crawled : 09:00) - biospace.com/
TAK | $13.185 0.27% 570K
|
Health Technology
|
| O: 0.75%
H: 0.63%
C: -0.17%
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
|
| O: 0.15%
H: 0.82%
C: -0.22%
covid vaccine approval covid-19
Japan’s Ministry of Health, Labour and Welfare (MHLW) Approves Moderna’s COVID-19 Vaccine
Published: 2021-05-21 (Crawled : 09:00) - biospace.com/
MRNA | News S | $101.87 -1.52% 710K
|
Health Technology
|
| O: 1.78%
H: 0.21%
C: -4.43%
covid vaccine approval health covid-19
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.